Human Liver Models Market Size (2024 - 2029)

Human Liver Models Market Analysis

The Human Liver Models Market size is estimated at USD 0.3 billion in 2024, and is expected to reach USD 0.46 billion by 2029, growing at a CAGR of 10.98% during the forecast period (2024-2029).

The COVID-19 pandemic had a significant impact on the market studied. As per the data from the CDC published in October 2021, the geriatric population included patients with serious underlying medical conditions, including people with liver disease, who were at a higher risk for severe illness from COVID-19. Patients with hepatocellular carcinoma (HCC), which occurs most often in people with chronic liver diseases, such as hepatitis B or hepatitis C, were at a higher risk for severe COVID-19 than those without hepatocellular carcinoma. However, during the pandemic, the focus of the healthcare industry was inclined toward COVID-19 management, which affected the market studied. Currently, the market has reached its pre-pandemic nature in terms of research and demand for human liver models and is expected to witness strong growth in the coming years.

The key factors responsible for the market growth include the increasing prevalence of liver diseases and advancements in organ printing technologies. In addition, the increasing focus on developing alternatives for animal-based models and accuracy in outcomes is projected to boost market growth. Moreover, the increasing prevalence of non-fatty acid liver disease and alcohol consumption that is leading to liver diseases is anticipated to fuel the market growth over the forecast period.

The change in the current lifestyle led to the exposure of a large population to certain risk factors that contribute to liver cancer. The risk factors include type-2 diabetes, hepatitis, metabolic disorders, excess body weight, alcohol consumption, and smoking. According to the GLOBOCAN data, globally, in 2020, there were around 905,677 (4.7%) new liver cancer cases and 830,180 (8.3%) deaths due to liver cancer. Moreover, the high demand for therapeutic drugs for liver cancer is expected to create wide opportunities for the market players for drug discovery with the help of liver models.

Hepatocellular carcinoma (HCC) and chronic liver disease are fatal illnesses with few curative alternatives. Therapeutic research is hampered by a shortage of experimental models that are clinically applicable and tractable. As per the data from Precision Bioscience published in September 2021, there is a significant unmet medical need for chemoprevention of liver disease progression toward cancer development due to the high prevalence of advanced liver fibrosis and cirrhosis, which are predicted to impact between 1% and 2% of the world's population. Therefore, with the rising prevalence of liver diseases, there is a growing demand for human liver models for study purposes, which is augmenting the market growth.

However, the high cost of liver models and issues with the incorporation of liver models into the existing workflow are expected to hamper the market growth over the forecast period.

Human Liver Models Industry Segmentation

As per the scope of this report, the liver is an important organ that performs vital body functions such as the synthesis of blood clotting factors, bile production, protein production, and detoxification. Human liver models are used to study the toxicity of the drug and enable an understanding of the effect of drugs and the progression of liver disease. The Human Liver Models Market is segmented by Product Type (2D Models, 3D Models, Liver-on-a-Chip, Other Product Types), Application (Education, Drug Discovery, Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value in USD for the above segments.